Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL-IV: 3D Regimen +/- Ribavirin in HCV GT1a
NCT01833533Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2013
- Primary completion
- Dec 2013
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of paritaprevir, ombitasvir, dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Mar 2013; status: completed.
02
Drugs
paritaprevirombitasvirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01833533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01833533.